Accolade

Accolade, Inc. engages in the provision of personalized health and benefits solutions. Its products include Accolade Total Benefits, which is designed for employers with low employee adoption of healthcare and benefits programs, Accolade Total Care, which focuses on influencing the actual interactions between employees and providers, and are also interested in care management services, and Accolade Total Health and Benefits, which offers a full suite of solutions. The company was founded by Thomas K. Spann, J. Michael Cline, and Sudhir Steven Singh in 2007 and is headquartered in Seattle, WA.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Accolade reports strong Q4 performance, faces market challenges ahead

Accolade's transformation into a personalized healthcare company has shown strong growth and improved financial performance. The company faces challenges related to operational excellence, market strategy, and the impact of industry decisions. However, opportunities lie in leveraging technology for healthcare and the upcoming Capital Markets Day to showcase growth prospects.

Accolade exceeds Q3 revenue guidance, eyes profitability by fiscal '25

Accolade's Q3 earnings call highlighted strong performance, diverse customer relationships, and growth opportunities in government business and virtual care. The company aims to achieve profitability by fiscal '25 through strategic investments and operational improvements, leveraging its competitive advantage in delivering ROI and performance guarantees.

Accolade reports robust Q4 performance, eyes tech-driven growth opportunities

Accolade's Q4 2023 Earnings Call highlighted strong financial performance, customer focus, and strategic initiatives. The company faces challenges in timing performance guarantees but sees opportunities in technology adoption and growth strategies.

Accolade surpasses Q1 expectations, eyes growth in healthcare partnerships

Accolade's Q1 performance exceeded expectations, with a focus on growth drivers and streamlining decision-making. Despite challenges in the government business, the company is optimistic about future growth opportunities and customer acquisition. Improved guidance and a strong pipeline indicate a positive outlook for the year.

Accolade beats Q2 revenue targets, eyes profitability in fiscal '25

Accolade exceeded revenue and EBITDA expectations in Q2, driven by strong customer additions and unique service offerings. Despite challenges from drug impacts and contract disputes, the company maintains its full-year guidance and eyes profitability in fiscal '25.

Accolade excels in Q3, eyes automation for growth opportunities

Accolade's Q3 performance exceeded expectations, with a positive outlook for future revenue and EBITDA. Differentiation in services and technology integration drive operational excellence. Uncertainty around TRICARE contract and focus on automation and growth opportunities.

Accolade reports robust Q4 earnings, eyes sustainable growth in '25

Accolade's strong performance in Q4 2024 sets a positive trajectory for fiscal year '25, with a focus on sustainable growth and profitability. The company's strategic strengths in serving a large customer base, successful partnerships, and innovative offerings position it well for future opportunities despite challenges in meeting revenue guidance and addressing post-security breach concerns.

Accolade reports strong Q2 earnings, focuses on profitability and growth

Accolade's Q2 performance exceeded expectations, emphasizing profitability and member experience.
The company's strengths lie in revenue growth, cost management, and competitive wins.
Challenges include cost structure management and balancing growth with profitability.
Opportunities exist in enhancing member experience, expanding partnerships, and driving sustainable growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Accolade, Inc. engages in the provision of technology-enabled health and benefits solutions. The company was founded by Thomas K. Spann and J. Michael Cline in January 2007 and is headquartered in Seattle, WA.

Accolade's full-year guidance was mixed, notwithstanding a Q1 FY 2025 results beat driven by a favorable timing factor. ACCD sees its revenue growth slowing from +14% last year to +13% in the current fiscal year, but its 3.7% FY 2025 EBITDA margin guidance was above expectations. My rating for Accolade is downgraded from a Buy to a Hold, after considering the company's outlook in light of its updated guidance.

Accolade: Mixed Guidance (Rating Downgrade)

LOS ANGELES--(BUSINESS WIRE)--ACCD Investors Have the Opportunity to Join Accolade, Inc. Securities Fraud Investigation with The Schall Law Firm.

ACCD Investors Have the Opportunity to Join Accolade, Inc. Securities Fraud Investigation with The Schall Law Firm

Accolade, Inc. (NASDAQ:ACCD ) Q1 2025 Earnings Conference Call June 27, 2024 4:30 PM ET Company Participants Todd Friedman - SVP of IR Rajeev Singh - CEO Steve Barnes - CFO Conference Call Participants Richard Close - Canaccord Genuity Craig Hettenbach - Morgan Stanley Michael Cherny - Leerink Partners Jeff Garro - Stephens Inc. Ryan Daniels - William Blair Jailendra Singh - Truist Securities Jessica Tassan - Piper Sandler Ryan MacDonald - Needham & Company Stephanie Davis - Barclays Stan Berenshteyn - Wells Fargo David Larsen - BTIG Jack Wallace - Guggenheim Securities Operator Hello, and thank you for standing by. Welcome to the Accolade First Quarter 2025 Earnings Results Conference Call.

Accolade, Inc. (ACCD) Q1 2025 Earnings Call Transcript

Accolade (ACCD) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.48. This compares to loss of $0.52 per share a year ago.

Accolade (ACCD) Reports Q1 Loss, Tops Revenue Estimates

SEATTLE, June 27, 2024 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD) today announced financial results for the fiscal first quarter ended May 31, 2024.

Accolade Announces Results for Fiscal First Quarter 2025

SEATTLE, June 12, 2024 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD) today announced that it will release fiscal first quarter 2025 financial results on Thursday, June 27, 2024, after the market closes. In conjunction, the company will host a conference call to review results at 4:30 p.m. E.T. on the same day.

Accolade to Announce Fiscal First Quarter 2025 Financial Results

The partnership combines Noom's best-in-class content and coaching with Accolade's advanced primary care physicians SEATTLE , May 21, 2024 /PRNewswire/ -- Accolade, Inc. (Nasdaq: ACCD) announced today that Noom has joined Accolade's Trusted Partner Ecosystem to provide customers with a comprehensive solution for weight loss and metabolic health, including support for GLP-1s and other anti-obesity medications. In addition to the standard integrated features that drive appropriate Trusted Partner utilization, Noom's clinical obesity management solution, Noom Med, will be powered by Accolade physicians extensively trained in weight loss protocols and advanced primary care.

Accolade Welcomes Noom to Trusted Partner Ecosystem

Accolade, Inc. (NASDAQ:ACCD ) Q4 2024 Earnings Conference Call April 25, 2024 4:30 PM ET Company Participants Todd Friedman - Senior Vice President of Investor Relations Rajeev Singh - Chief Executive Officer Steve Barnes - Chief Financial Officer Conference Call Participants Jailendra Singh - Trust Securities Stephanie Davis - Barclays Ryan Daniels - William Blair Michael Cherny - Leerink Partners Richard Close - Canaccord Genuity Craig Hettenbach - Morgan Stanley Jeff Garro - Stephens Ryan MacDonald - Needham & Company Jessica Tassan - Piper Sandler David Larsen - BTIG Stanislav Berenshteyn - Wells Fargo Operator Hello and thank you for standing by. Welcome to Accolade Fourth Quarter 2024 Earnings Results Conference Call.

Accolade, Inc. (ACCD) Q4 2024 Earnings Call Transcript

Accolade (ACCD) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to loss of $0.42 per share a year ago.

Accolade (ACCD) Reports Q4 Loss, Tops Revenue Estimates

SEATTLE, April 25, 2024 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD) today announced financial results for the fiscal fourth quarter and full year ended February 29, 2024.

Accolade Announces Results for Fiscal Fourth Quarter and Full Year 2024

I like Accolade's choice of new partners added year-to-date, as I think the services provided by these partners will be well received by its clients' employees. ACCD's latest "Artificial Intelligence Excellence Award" presented by the Business Intelligence Group provides a validation of the potential AI-related tailwinds for the company. A review of Accolade's most recent developments leaves me bullish on the stock.

Accolade: Staying Bullish On Favorable Developments

Award recognizes the innovative blend of AI technology with an empathetic human approach to deliver exceptional healthcare experiences for members SEATTLE , March 20, 2024 /PRNewswire/ -- Accolade, Inc. (Nasdaq: ACCD) today announced it has been named a winner of the Business Intelligence Group's Artificial Intelligence Excellence Awards program for its application of Natural Language Processing. This award recognizes companies leveraging AI technology to solve real-world problems.

Accolade Wins 2024 Artificial Intelligence Excellence Award

LITTLE ROCK, Ark.--(BUSINESS WIRE)--In an industry where connection and quality of service matter most, Arkansas-based Kinetic was recognized and honored by Forbes Home for its “Best Rural High Speeds” in the recent article “Best Internet Options for Rural Areas of 2024.” This Forbes Home accolade is a testament to Kinetic's pledge to bring affordable, fast and reliable internet to rural areas. Kinetic was selected by a team of Forbes Home licensed professionals comparing 38 attributes across 2.

National Accolade Bestowed on Arkansas-Based Provider: ‘Best Rural High Speeds'

McDonald Harris assumes new role on Executive Leadership Team to deliver an exceptional employee experience and support the growth and development of its 2,400+ global workforce SEATTLE , March 19, 2024 /PRNewswire/ -- Accolade, Inc. (Nasdaq: ACCD) announced today the promotion of Kelsi McDonald Harris as Chief People Officer and Senior Vice President. "Transforming healthcare in this country requires visionary human resources leaders who are willing to challenge the status quo," said Rajeev Singh, Chairman and CEO at Accolade.

Accolade Promotes Kelsi McDonald Harris to Chief People Officer

Chesapeake Financial Shares Inc. (OTCQX:CPKF)'s Chesapeake Bank was honored by the American Association of Retired Persons (AARP) for its steadfast efforts in combatting financial exploitation. On March 6, AARP revealed the recognition of Chesapeake Bank among a cohort of 166 banks, credit unions, and financial advisory firms bestowed with the prestigious BankSafe Trained Seal.

Chesapeake Bank receives AARP accolade for combatting financial exploitation

Partnership expands access to high-quality, affordable adolescent and children's behavioral health services SEATTLE , Feb. 27, 2024 /PRNewswire/ -- Accolade, Inc. (Nasdaq: ACCD) announced today that Brightline, a comprehensive pediatric behavioral health solution built for children, teens, their parents, and caregivers, has joined the company's Trusted Partner Ecosystem. The Brightline partnership builds on Accolade's existing behavioral health partnerships with Headspace, Lyra, and Equip and internal capabilities, including an in-house behavioral health advocacy team, Accolade Care therapists, and consulting psychiatrists.

Accolade Welcomes Brightline to Trusted Partner Ecosystem

Progyny

This week brought another blow for reproductive rights in the U.S. An Alabama Supreme Court handed down a ruling that not only can frozen embryos be classified as “children,” but destroying them can lead to charges of wrongful death. This decision has prompted the University of Alabama at Birmingham, the state's largest healthcare provider, to cease all in vitro fertilization (IVF) treatments.

Alabama's Fertility Ruling Raises Challenges for Stocks of Fertility Benefits Providers

Here is how Accolade (ACCD) and Palantir Technologies Inc. (PLTR) have performed compared to their sector so far this year.

Are Business Services Stocks Lagging Accolade (ACCD) This Year?

The consensus price target hints at a 25.6% upside potential for Accolade (ACCD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Does Accolade (ACCD) Have the Potential to Rally 25.58% as Wall Street Analysts Expect?

AxoGen

Credo Technology Group Holding Ltd

Western Digital

Invest in stocks such as AxoGen (AXGN), Western Digital (WDC), Accolade (ACCD) and Credo Technology (CRDO) for superb earnings acceleration.

4 Top Stocks That Flaunt Solid Earnings Acceleration

Kindbody partnership builds on Accolade's commitment to offer best-in-class women's health, fertility and family-forming capabilities for customers and members SEATTLE , Jan. 23, 2024 /PRNewswire/ -- Accolade, Inc. (Nasdaq: ACCD) today announced that Kindbody, a technology-driven fertility clinic network and family-building benefits provider for employers, will join the company's Trusted Partner Ecosystem to offer Accolade customers comprehensive, clinically guided support and care throughout a member's fertility and family-building journey, all backed by a new cost savings performance guarantee. Approximately one in six couples are affected by infertility in the United States.

Accolade Welcomes Kindbody to Trusted Partner Ecosystem

LITTLE ROCK, Ark.--(BUSINESS WIRE)--Technology and consumer electronics website CNET has bestowed its “Best of” accolade on Kinetic as the “Best for Fast DSL Internet Speeds.” This is the second consecutive year Kinetic has received the CNET recognition. “DSL is an excellent option for rural areas,” CNET writes on the website's 2024 awards page, “and it doesn't come with a number of the drawbacks and problems of satellite service, such as high latency and strict data caps, for instance. Its pri.

CNET Bestows ‘Best of Internet Providers of 2024' accolade to Kinetic

The consensus price target hints at a 26.9% upside potential for Accolade (ACCD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Predict a 26.85% Upside in Accolade (ACCD): Here's What You Should Know

Accolade (ACCD) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Why Accolade (ACCD) Stock Might be a Great Pick

I continue to recommend a buy rating with a projected 20% growth in FY25. Recent results show that Accolade beat consensus estimates for revenue and EBITDA, and management expects 20% revenue growth and 2-4% EBITDA margins in FY25. Tailwinds for growth include strong demand for navigation solutions, the health plan channel strategy, GLP-1 growth catalyst, and the recovery in demand for expert medical opinion.

News for Accolade Stock (ACCD)